This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Shareholders Of ZymoGenetics, Inc.

Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of ZymoGenetics, Inc. (“ZymoGenetics” or the “Company”) (NASDAQ:ZGEN) related to the Company’s agreement to be acquired by Bristol-Myers Squibb Company (“Bristol-Myers”). The proposed transaction is valued at approximately $885 million.

Under the terms of the definitive agreement entered into by the parties, a wholly owned subsidiary of Bristol-Myers has commenced a cash tender offer to purchase all of the outstanding shares of ZymoGenetics common stock for $9.75 per share. Shareholders holding approximately 37% of the outstanding shares of ZymoGenetics common stock have entered into agreements with Bristol-Myers to tender their shares in the offer. In addition, the merger agreement includes a provision under which ZymoGenetics has agreed not to solicit any competing offers for the Company. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by ZymoGenetics’ board of directors.

If you own shares of ZymoGenetics, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $129.96 0.00%
FB $80.44 0.00%
GOOG $539.18 0.00%
TSLA $248.35 0.00%
YHOO $43.15 0.00%

Markets

DOW 18,011.94 -28.43 -0.16%
S&P 500 2,109.60 -2.13 -0.10%
NASDAQ 5,076.5240 -6.4050 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs